查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1629834

全球糖尿病数位治疗市场 - 2024-2031

Global Digital Therapeutics for Diabetes Market - 2024-2031
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

2023年，全球糖尿病数位治疗市场规模达16亿美元，预计2033年将达53亿美元，2025-2033年预测期间复合年增长率为12.9%。

糖尿病数位疗法是指一类基于证据、软体驱动的解决方案，旨在利用数位技术、行为科学和个人化资料来预防、管理或治疗糖尿病。这些解决方案旨在作为独立疗法或与药物和胰岛素等传统疗法结合使用。他们的目标是透过即时监测、行为矫正和病患教育，解决糖尿病的根本原因，如生活型态因素、药物依从性和血糖调节，帮助病患管理病情。

由于糖尿病盛行率不断上升以及持续疾病管理的需求，对糖尿病数位疗法的需求正在显着增长。这一成长主要得益于智慧型手机和数位健康技术的日益普及，这些技术为糖尿病等慢性病提供了经济高效、可扩展和个人化的管理解决方案。例如，根据彼得森健康科技研究所(PHTI) 的说法，数位糖尿病管理解决方案对购买者的经济影响取决于数位解决方案的价格以及它如何影响医疗保健利用模式和使用该解决方案的患者的支出。它假设合格用户的采用率为 25%。

市场动态：

驱动程式和限制

糖尿病盛行率上升

糖尿病盛行率的上升极大地推动了糖尿病数位疗法市场的成长，并且预计将在预测期内推动市场的发展，因为越来越多的糖尿病患者被诊断出需要新的、可扩展的和有效的治疗方案。数位疗法被视为管理糖尿病的有效方法，特别是随着对远端护理、个人化治疗计划和即时监测的需求不断增长。

例如，根据国际糖尿病联盟的数据，2021 年，5.366 亿成年人（20-79 岁）患有糖尿病，即十分之一。预计到 2030 年，这一数字将增加至 6.428 亿，到 2045 年将增至 7.837 亿。 2021 年，糖尿病将导致 670 万人死亡——每 5 秒就有 1 人死于糖尿病。 5.41 亿成年人患有葡萄糖耐受性受损 (IGT)，这使他们面临第 2 型糖尿病的高风险。这种不断上升的盛行率凸显了对易于使用且具有成本效益的糖尿病管理解决方案的迫切需求。

糖尿病是一种需要终身管理的慢性疾病，数位治疗提供了一种持续监测和调整治疗计划的手段。数位平台和连接设备，如连续血糖监测仪 (CGM)、行动应用程式和胰岛素剂量追踪器，提供即时资料，从而实现更个人化的护理。这对于第 1 型和 2 型糖尿病族群特别有用，因为遵守治疗计划至关重要。

例如，BlueStar（由Welldoc 提供支援）是一种用于糖尿病管理的数位治疗解决方案，它与胰岛素剂量建议和持续血糖监测相结合，以提供个人化指导，这表明数位治疗在日常糖尿病管理中日益重要。

资料隐私问题

资料隐私问题是糖尿病市场数位疗法发展的重大障碍，因为它们直接影响信任、采用率和监管合规性。数位疗法涉及敏感健康资料的收集和处理，例如血糖水平、胰岛素剂量和生活习惯，这引起了人们对这些资讯的安全、储存和共享的担忧。

用于糖尿病管理的数位健康平台通常要求使用者输入个人健康资讯，包括来自连续血糖监测仪 (CGM) 或智慧胰岛素笔等设备的即时资料。这些资料高度敏感，必须极度谨慎地处理，以避免可能洩露个人健康资讯的外洩。

例如，根据 HIPAA 杂誌报导，2023 年 8 月，发现有 2,300 万笔医疗记录被洩露。在过去 12 个月中，平均每月有 9,989,003 笔医疗记录被洩露。截至 2024 年 8 月 31 日的一年内，已发生 491 起资料外洩事件，涉及 500 笔或更多记录，已知至少 58,668,002 笔记录已外洩。目前，2024 年的平均外洩规模为 119,487 笔记录，中位外洩规模为 4,109 笔记录。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分類的片段
  • 按应用程式片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 糖尿病盛行率上升
      • 不断进步的技术
    • 限制
      • 资料隐私问题
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：糖尿病市场的数位治疗，依产品类型

  • 软体解决方案
    • 行动应用程式
    • 网路为基础的解决方案
  • 硬体解决方案
    • 穿戴式装置
    • 连续血糖监测仪
    • 其他的

第 6 章：糖尿病市场的数位治疗（按应用）

  • 1 型糖尿病
  • 2 型糖尿病
  • 糖尿病前期

第 7 章：最终用户的糖尿病市场数位治疗

  • 医院
  • 专科诊所
  • 家庭护理设置
  • 其他的

第 8 章：糖尿病市场的数位治疗，按区域市场分析和成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 9 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 10 章：公司简介

  • Welldoc, Inc.
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • Omada Health Inc.
  • Glooko, Inc.
  • Azumio Inc.
  • Abbott Laboratories
  • mySugr GmbH
  • Dexcom, Inc.
  • Health2Sync
  • iHealth Labs Inc.
  • Medtronic plc

第 11 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 12 章：附录

简介目录
Product Code: MD8884

The global digital therapeutics for diabetes market reached US$ 1.6 billion in 2023 and is expected to reach US$ 5.3 billion by 2033, growing at a CAGR of 12.9% during the forecast period 2025-2033.

Digital therapeutics for diabetes refers to a category of evidence-based, software-driven solutions designed to prevent, manage or treat diabetes, leveraging digital technology, behavioral science and personalized data. These solutions are intended to be used either as stand-alone therapies or in conjunction with traditional treatments such as medications and insulin. They aim to help patients manage their condition by addressing the root causes of diabetes, such as lifestyle factors, medication adherence and glucose regulation, through real-time monitoring, behavior modification and patient education.

The demand for digital therapeutics for diabetes is experiencing significant growth, driven by the increasing prevalence of diabetes and the need for continuous disease management. This growth is primarily fueled by the rising adoption of smartphones and digital health technologies, which provide cost-effective, scalable and personalized management solutions for chronic diseases like diabetes. For instance, according to the Peterson Health Technology Institute (PHTI), the economic impact on purchasers of digital diabetes management solutions depends on the price of the digital solution and how it affects patterns of healthcare utilization and spending for patients who use them. It assumes a 25% adoption rate among eligible users.

Market Dynamics: Drivers & Restraints

Rising prevalence of diabetes

The rising prevalence of diabetes is significantly driving the growth of the digital therapeutics for diabetes market and is expected to drive the market over the forecast period, as the increasing number of people diagnosed with diabetes necessitates new, scalable and effective treatment options. Digital therapeutics are seen as an efficient way to manage diabetes, especially with the growing demand for remote care, personalized treatment plans and real-time monitoring.

For instance, according to the International Diabetes Federation, in 2021, 536.6 million adults (20-79 years) are living with diabetes i.e., 1 in 10 people. This number is predicted to rise to 642.8 million by 2030 and 783.7 million by 2045. Over 3 in 4 adults with diabetes live in low- and middle-income countries. Diabetes is responsible for 6.7 million deaths in 2021 - 1 every 5 seconds. 541 million adults have Impaired Glucose Tolerance (IGT), which places them at high risk of type 2 diabetes. This escalating prevalence highlights the urgent need for accessible and cost-effective diabetes management solutions.

Diabetes is a chronic condition requiring lifelong management and digital therapeutics provide a means to continuously monitor and adjust treatment plans. Digital platforms and connected devices, like continuous glucose monitors (CGMs), mobile apps, and insulin dose trackers, offer real-time data, allowing for more personalized care. This is particularly useful for the Type 1 and Type 2 diabetes populations, where adherence to treatment plans is crucial.

For instance, BlueStar (powered by Welldoc), a digital therapeutic solution for diabetes management, integrates with insulin dosing recommendations and continuous glucose monitoring to provide personalized guidance, demonstrating the growing importance of digital therapeutics in day-to-day diabetes management.

Data privacy concerns

Data privacy concerns are a significant barrier to the growth of digital therapeutics for the diabetes market, as they directly impact trust, adoption rates and regulatory compliance. Digital therapeutics involve the collection and processing of sensitive health data, such as glucose levels, insulin doses and lifestyle habits, which raises concerns regarding the security, storage and sharing of this information.

Digital health platforms for diabetes management often require users to input personal health information, including real-time data from devices like continuous glucose monitors (CGMs) or smart insulin pens. This data, being highly sensitive, must be handled with the utmost care to avoid breaches that could expose personal health information.

For instance, according to the HIPAA Journal, in August 2023, 23 million breached healthcare records are noticed. Over the past 12 months, an average of 9,989,003 healthcare records were breached each month. In the year to August 31, 2024, there have been 491 data breaches of 500 or more records, and at least 58,668,002 records are known to have been breached. The average breach size in 2024 is currently 119,487 records and the median breach size is 4,109 records.

Segment Analysis

The global digital therapeutics for diabetes market is segmented based on product type, application, end-user and region.

Product Type:

The software solutions segment is expected to dominate the digital therapeutics for diabetes market share

The software solutions segment is expected to dominate the global digital therapeutics for diabetes market. Software-based solutions such as mobile apps and digital platforms allow patients to track glucose levels, insulin use, diet and physical activity, providing personalized feedback and treatment recommendations. For instance, in November 2024, PureHealth revealed a huge surge in users of Pura, the group's AI-enabled app. With over 140,000 downloads to date, Pura aims to improve quality of life and lifespans by providing individuals with personalized data, empowering them to improve their health through user-friendly tools and tailored insights.

Mobile and web-based applications are easy to use and accessible for a wide range of patients, including those in rural or underserved areas. The growing smartphone penetration is a key factor in this segment's dominance. For instance, in November 2023, Abbott launched its digital health tool, FreeStyle LibreLink app in India. The mobile app allows people who use the FreeStyle Libre system to measure their glucose readings on their mobile phones without pricking. The mobile app is compatible with iPhone and Android smartphones.

The integration of digital therapeutics software with wearable devices like continuous glucose monitors and smart insulin pens allows for seamless, continuous monitoring of diabetes. These integrations are essential for patients with Type 1 and Type 2 diabetes, who need real-time adjustments to their insulin and lifestyle. As mentioned above, Abbott's Freestyle Libre, connects with mobile apps to provide real-time glucose tracking, demonstrating the growing adoption of software solutions in diabetes management.

Geographical Analysis

North America is expected to hold a significant position in the digital therapeutics for diabetes market share

North America is expected to hold the largest market share in the global digital therapeutics for diabetes market. North America, particularly the United States, has a high diabetes prevalence, which fuels the demand for digital therapeutics solutions. For instance, according to the Centers for Disease Control and Prevention (CDC), In 2021, 29.7 million people of all ages or 8.9% of the U.S. population had been diagnosed with diabetes and the number is expected to rise as the population ages. This includes 304,000 with type 1 diabetes. 3.6 million adults aged 20 years or older or 12.3% of all U.S. adults with diagnosed diabetes and started using insulin within a year of their diagnosis.

The United States has one of the highest rates of smartphone and internet penetration globally, making it an ideal market for the adoption of digital health solutions like mobile apps and wearable devices. This technological infrastructure is pivotal for the adoption of digital therapeutics platforms that require constant connectivity for real-time data sharing and analysis. For instance, new National Telecommunications and Information Administration (NTIA) data showed 13 million more internet users in the U.S. in 2023 than in 2021.

Digital health solutions like Welldoc's BlueStar and Omada Health's digital platform for diabetes management have gained significant traction in the U.S., further solidifying North America's leadership in the space.

Asia-Pacific is growing at the fastest pace in the digital therapeutics for diabetes market

The Asia-Pacific region is experiencing the fastest growth in the digital therapeutics for diabetes market. There is a strong push towards digital health and telemedicine in countries like India, China and Australia, where smartphone penetration is rapidly increasing.

For instance, India had over 700 million active internet users aged 2 years and above as of December 2022, according to Nielsen's India Internet Report 2023. Of these, rural India accounted for 425 million users, which was almost 44% higher than the number of active internet users in urban areas, with 295 million users, providing a strong foundation for the growth of mobile-based digital therapeutics platforms.

Several APAC countries have launched initiatives to support digital health technologies. For example, China's "Healthy China 2030" plan aims to enhance healthcare infrastructure, which includes the adoption of digital health tools for chronic disease management.

Competitive Landscape

The major global players in the digital therapeutics for diabetes market include Welldoc, Inc., Omada Health Inc., Glooko, Inc., Azumio Inc., Abbott Laboratories, mySugr GmbH, Dexcom, Inc., Health2Sync, iHealth Labs Inc., Medtronic plc and among others.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global digital therapeutics for diabetes market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Application
  • 2.5. Snippet by End-User
  • 2.6. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Prevalence of Diabetes
      • 3.1.1.2. Rising Technological Advancements
    • 3.1.2. Restraints
      • 3.1.2.1. Data Privacy Concerns
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Digital Therapeutics for Diabetes Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Software Solutions*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
    • 5.2.3. Mobile Apps
    • 5.2.4. Web-Based Solutions
  • 5.3. Hardware Solutions
    • 5.3.1. Wearable Devices
    • 5.3.2. Continuous Glucose Monitors
    • 5.3.3. Others

6. Digital Therapeutics for Diabetes Market, By Application

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 6.1.2. Market Attractiveness Index, By Application
  • 6.2. Type-1 Diabetes*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Type-2 Diabetes
  • 6.4. Pre-Diabetes

7. Digital Therapeutics for Diabetes Market, By End-User

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 7.1.2. Market Attractiveness Index, By End-User
  • 7.2. Hospitals*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Specialty Clinics
  • 7.4. Homecare Settings
  • 7.5. Others

8. Digital Therapeutics for Diabetes Market, By Regional Market Analysis and Growth Opportunities

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 8.1.2. Market Attractiveness Index, By Region
  • 8.2. North America
    • 8.2.1. Introduction
    • 8.2.2. Key Region-Specific Dynamics
    • 8.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.2.6.1. U.S.
      • 8.2.6.2. Canada
      • 8.2.6.3. Mexico
  • 8.3. Europe
    • 8.3.1. Introduction
    • 8.3.2. Key Region-Specific Dynamics
    • 8.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.3.6.1. Germany
      • 8.3.6.2. U.K.
      • 8.3.6.3. France
      • 8.3.6.4. Spain
      • 8.3.6.5. Italy
      • 8.3.6.6. Rest of Europe
  • 8.4. South America
    • 8.4.1. Introduction
    • 8.4.2. Key Region-Specific Dynamics
    • 8.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.4.6.1. Brazil
      • 8.4.6.2. Argentina
      • 8.4.6.3. Rest of South America
  • 8.5. Asia-Pacific
    • 8.5.1. Introduction
    • 8.5.2. Key Region-Specific Dynamics
    • 8.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 8.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 8.5.6.1. China
      • 8.5.6.2. India
      • 8.5.6.3. Japan
      • 8.5.6.4. South Korea
      • 8.5.6.5. Rest of Asia-Pacific
  • 8.6. Middle East and Africa
    • 8.6.1. Introduction
    • 8.6.2. Key Region-Specific Dynamics
    • 8.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 8.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
    • 8.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

9. Competitive Landscape and Market Positioning

  • 9.1. Competitive Overview and Key Market Players
  • 9.2. Market Share Analysis and Positioning Matrix
  • 9.3. Strategic Partnerships, Mergers & Acquisitions
  • 9.4. Key Developments in Product Portfolios and Innovations
  • 9.5. Company Benchmarking

10. Company Profiles

  • 10.1. Welldoc, Inc.*
    • 10.1.1. Company Overview
    • 10.1.2. Product Portfolio and Description
    • 10.1.3. Financial Overview
    • 10.1.4. Key Developments
    • 10.1.5. SWOT Analysis
  • 10.2. Omada Health Inc.
  • 10.3. Glooko, Inc.
  • 10.4. Azumio Inc.
  • 10.5. Abbott Laboratories
  • 10.6. mySugr GmbH
  • 10.7. Dexcom, Inc.
  • 10.8. Health2Sync
  • 10.9. iHealth Labs Inc.
  • 10.10. Medtronic plc

LIST NOT EXHAUSTIVE

11. Assumption and Research Methodology

  • 11.1. Data Collection Methods
  • 11.2. Data Triangulation
  • 11.3. Forecasting Techniques
  • 11.4. Data Verification and Validation

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us